Celltrion unveils results of phase 2 clinical trials for corona antibody treatment

The results of the Phase 2 clinical trial of Celltrion’s Corona 19 antibody treatment’Rekironaju’ will be released on the 13th of this month.

According to industry sources on the 5th, Celltrion decided to participate in the 2021 High1 New Drug Development Symposium hosted by the Korean Pharmacopoeia on the 13th of this month and announce the results of the global clinical phase 2 of Rekkirona.

Currently, Celltrion has completed phase 2 of the global clinical trial in Rekirona and has applied for conditional approval from the Ministry of Food and Drug Safety.

Phase 2 clinical trials were conducted on a total of 327 mild and moderate corona19 patients in Korea and Romania, and medication was completed on November 25 of last year.

Nevertheless, detailed clinical data were not disclosed. However, as interest in clinical results increases, it is observed that data are released sooner than originally planned.

Celltrion plans to announce the results of phase 2 clinical trials of Rekirona at an international conference soon.

On the other hand, Celltrion is also planning to enter phase 3 clinical trials for COVID-19 antibody treatments in more than 10 countries around the world.